PARP Inhibitors and Ovarian Cancer -- Sloan-Kettering

Medical oncologist Katherine Bell-McGuinn describes a novel class of ovarian cancer therapies called PARP inhibitors. These drugs, which are in development at Memorial Sloan-Kettering Cancer Center, are designed to block a protein called PARP that causes tumor cells to grow uncontrollably. (In normal cells, PARP helps repair damaged DNA.) This approach could help the 10% of patients who have deficiencies in another protein called BRCA, which is also involved in DNA repair, and whose cells therefore rely more heavily on PARP to repair DNA breaks within tumor cells.

For more information, please visit http://www.mskcc.org/ovariancancer

Category:

Science & Technology

Tags:

• ovarian cancer
• PARP
• clinical trials
• BRCA1
• BRCA2
• AZD2281
• BSI-201
• chemotherapy
• side effects
• Katherine Bell-McGuinn
• Sloan-Kettering